High-dose inhaled beclomethasone treatment in patients with chronic cough: a randomized placebo-controlled study

Página do item simplificado
dc.contributor.authorRibeiro, Marcos [UNIFESP]
dc.contributor.authorPereira, Carlos Alberto de Castro [UNIFESP]
dc.contributor.authorNery, Luiz Eduardo [UNIFESP]
dc.contributor.authorBeppu, Osvaldo Shigueomi [UNIFESP]
dc.contributor.authorSilva, Clystenes Odyr Soares [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2018-06-15T13:50:11Z
dc.date.available2018-06-15T13:50:11Z
dc.date.issued2007-07-01
dc.description.abstractBackground: It is important to determine whether chronic cough is associated with asthma and can be helped by treatment with inhaled corticosteroids.Objective: To compare the effects of beclomethasone and placebo in patients with chronic cough for at least 8 weeks after excluding those with cough due to postnasal drip and gastroesophageal reflux disease.Methods: A prospective, randomized, double-blind, placebo-controlled study comprising 64 patients was performed for 2 weeks. The active group received metered-dose inhaler chlorofluorocarbon-beclomethasone (1,500 mu g/d), and the placebo group C received identical-appearing placebo inhalers. All the participants completed a respiratory questionnaire and underwent bronc, choprovocation testing (BPT) with methacholine and allergy skin testing. The primary outcome measure was a decrease in daily cough scores (symptom diary and visual analog scale) during the 2-week treatment period.Results: The active group comprised 44 patients and the placebo group 20 patients. Cough duration averaged 20 weeks. At the end of treatment 82% of the active group and 15% of the placebo group had complete resolution of cough. In the active group 22 patients (50%) had positive BPT results, and in the placebo group 10 patients (50%) had positive results. There was no correlation between treatment response and responses on the respiratory questionnaire, allergy skin testing, or BPT.Conclusion: Therapy with high-dose inhaled beclomethasone provided an excellent response in a subgroup of patients with chronic cough that did not correlate with atopy or airway hyperresponsiveness.en
dc.description.affiliationUniv Fed Sao Paulo, Dept Med, Div Resp, BR-01228000 Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Dept Med, Div Resp, BR-01228000 Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent61-68
dc.identifierhttp://dx.doi.org/10.1016/S1081-1206(10)60623-0
dc.identifier.citationAnnals Of Allergy Asthma & Immunology. Arlington Hts: Amer Coll Allergy Asthma Immunology, v. 99, n. 1, p. 61-68, 2007.
dc.identifier.doi10.1016/S1081-1206(10)60623-0
dc.identifier.issn1081-1206
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/42559
dc.identifier.wosWOS:000248072800012
dc.language.isoeng
dc.publisherAmer Coll Allergy Asthma Immunology
dc.relation.ispartofAnnals Of Allergy Asthma & Immunology
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.titleHigh-dose inhaled beclomethasone treatment in patients with chronic cough: a randomized placebo-controlled studyen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos